This is a series on the advances in CAR T, a remarkable immunotherapy treatment dubbed a “living drug.” This new therapy genetically modifies a patient’s cells to fight cancer, but current research efforts hope to treat autoimmune diseases, organ damage and more.
The experience of attending Rare Disease Day at the National Institutes of Health (NIH) exceeded the confines of the definition for rare and instead should be more appropriately defined as extraordinary shares a new Medika author.
